MRK Merck & Co., Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 310158 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.9%
TTM net income YoY-87.1%
TTM EPS YoY-86.9%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR-19.0%
Margins
Gross margin71.8%
Operating margin—
Net margin3.6%
FCF margin21.9%
EBITDA margin—
Returns
ROE5.1%
ROA1.9%
ROIC (approx.)—
Asset turnover0.51x
Leverage & solvency
Liabilities / assets66.1%
Debt / equity1.20x
Current ratio1.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income7.62x
Accruals ratio-12.4%
Payout ratio341.1%
Capex / revenue5.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B |
| Cost of revenue | $16.38B | $15.19B | $16.13B | $17.41B | $13.63B |
| Gross profit | $48.63B | $48.98B | $43.99B | $41.87B | $35.08B |
| R&D expense | $15.79B | $17.94B | $30.53B | $13.55B | $12.24B |
| SG&A expense | $10.73B | $10.82B | $10.50B | $10.04B | $9.63B |
| Interest expense | $1.36B | $1.27B | $1.15B | $962.00M | $806.00M |
| Pretax income | $21.07B | $19.94B | $1.89B | $16.44B | $13.88B |
| Income tax | $2.80B | $2.80B | $1.51B | $1.92B | $1.52B |
| Net income | $18.25B | $17.12B | $365.00M | $14.52B | $13.05B |
| EPS (basic) | 7.30 | 6.76 | 0.14 | 5.73 | 5.16 |
| EPS (diluted) | 7.28 | 6.74 | 0.14 | 5.71 | 5.14 |
| Dividends declared per share | 3.28 | 3.12 | 2.96 | 2.80 | 2.64 |
| Weighted avg. shares (diluted) | 2.51B | 2.54B | 2.55B | 2.54B | 2.54B |
| Balance sheet | |||||
| Cash & equivalents | $14.56B | $13.32B | $6.91B | $12.77B | $8.17B |
| Short-term investments | $0 | $447.00M | $252.00M | $498.00M | $0 |
| Receivables | $11.78B | $10.28B | $10.35B | $9.45B | $9.23B |
| Inventory | $6.66B | $6.11B | $6.36B | $5.91B | $5.95B |
| Current assets | $43.52B | $38.78B | $32.17B | $35.72B | $30.27B |
| PP&E, net | $25.32B | $23.78B | $23.05B | $21.42B | $19.28B |
| Goodwill | $21.58B | $21.67B | $21.20B | $21.20B | $21.26B |
| Intangibles | $26.68B | $16.37B | $18.01B | $20.27B | $22.93B |
| Total assets | $136.87B | $117.11B | $106.67B | $109.16B | $105.69B |
| Current liabilities | $28.33B | $28.42B | $25.69B | $24.24B | $23.87B |
| Short-term debt | $2.59B | $2.65B | $1.37B | $1.95B | $2.41B |
| Long-term debt | $46.75B | $34.46B | $33.68B | $28.75B | $30.69B |
| Total debt | $49.34B | $37.11B | $35.05B | $30.69B | $33.10B |
| Total liabilities | $84.20B | $70.73B | $69.04B | $63.10B | $67.44B |
| Shareholders' equity | $52.61B | $46.31B | $37.58B | $45.99B | $38.18B |
| Net debt | $34.77B | $23.79B | $28.15B | $17.92B | $24.93B |
| Cash flow statement | |||||
| Operating cash flow | $16.47B | $21.47B | $13.01B | $19.09B | $13.12B |
| Capital expenditure | $4.11B | $3.37B | $3.86B | $4.39B | $4.45B |
| Free cash flow | $12.36B | $18.10B | $9.14B | $14.71B | $8.67B |
| Investing cash flow | -$13.74B | -$7.73B | -$14.08B | -$4.96B | -$16.42B |
| Financing cash flow | -$1.92B | -$7.03B | -$4.81B | -$9.12B | $3.10B |
| Depreciation & amortization | $3.04B | $2.10B | $1.83B | $1.82B | $1.58B |
| Stock-based compensation | $820.00M | $761.00M | $645.00M | $541.00M | $479.00M |
| Dividends paid | $8.18B | $7.84B | $7.45B | $7.01B | $6.61B |
| Share buybacks | $5.08B | $1.31B | $1.35B | $0 | $840.00M |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.